- 专利标题： METHODS OF DETERMINING WHETHER A SUBJECT HAS OR IS AT RISK OF HAVING A CENTRAL SEROUS CHORIORETINOPATHY
-
申请号： US17905899申请日： 2021-03-10
-
公开(公告)号： US20230151425A1公开(公告)日： 2023-05-18
- 发明人: Francine BEHAR-COHEN , Min ZHAO
- 申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Sorbonne Université , Université Paris Cité , Assistance Publique-Hôpitaux de Paris , Fondation Asile des Aveugles
- 申请人地址： FR Paris
- 专利权人： INSERM (Institut National de la Santé et de la Recherche Médicale),Sorbonne Université,Université Paris Cité,Assistance Publique-Hôpitaux de Paris,Fondation Asile des Aveugles
- 当前专利权人： INSERM (Institut National de la Santé et de la Recherche Médicale),Sorbonne Université,Université Paris Cité,Assistance Publique-Hôpitaux de Paris,Fondation Asile des Aveugles
- 当前专利权人地址： FR Paris
- 优先权： WO 305253.5 2020.03.11
- 国际申请： PCT/EP2021/056109 2021.03.10
- 进入国家日期： 2022-09-08
- 主分类号： C12Q1/6883
- IPC分类号： C12Q1/6883 ; A61K31/585
摘要：
Central Serous chorioretinopathy (CSCR) is primarily an ocular disease, affecting the choroid and the retinal pigment epithelium. To date, no systemic biomarker of CSCR have been discovered that could link both forms and help the diagnosis in challenging cases. In the present invention, the inventors measure in European cohorts of CSCR patients (n=168) with (n=90) or without epitheliopathy (n=78) and a cohort of 153 control subjects without any ocular disease history, the serum levels of NGAL and the NGAL/MMP9 complex. Serum NGAL (ng/ml) was significantly higher in the control group (108.8±46.8) than in the CSCR cohort (80.4±46.4, p
信息查询
